UNSPSC 51144130: Phentermine

This classification denotes an anorexiant with the molecular formula C10H15N, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) C045TQL4WP, chemically known as 1,1-dimethyl-2-phenylethylamine but more generally known as phentermine, which bears US NIH Compound Identifier 4771. European Medicines Agency schedules Phentermine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09784MIG.

UNSPSC 51144130 Phentermine is a Commodity code that encompasses pharmaceutical products purchased by state and local health and human services agencies, though recent solicitations under this code show activity across a broader spectrum of prescription and over-the-counter medications rather than phentermine specifically. State and local governments procure pharmaceuticals through a mix of issuing bodies including county health departments, state health and human services commissions, and cooperative purchasing alliances that serve multiple jurisdictions. The scope of work reflects bulk procurement of FDA-compliant generic and branded pharmaceutical products, including controlled substances and OTC items, with vendors required to maintain cGMP certification, DSCSA compliance, established relationships with licensed wholesalers, and adherence to federal and state pharmaceutical supply chain regulations. Procurement typically includes detailed product specification requirements (NDC codes, SKUs, UPCs, strength, dosage form, packaging configurations), multi-year contracts with renewal options, quarterly or as-needed delivery schedules, and fixed-price or net-price pricing models.

Recent activity spans Florida, Texas, and Minnesota, with the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) issuing a significant RFP on January 20, 2026 for generic multi-source pharmaceuticals and OTC products distributed across state and local facilities in Minnesota and Oregon, with a response deadline of March 26, 2026. Seminole County, Florida released an IFB (solicitation number IFB60459723LAS) on June 30, 2026 for 1,900 units of naloxone and 800 safe drug deactivation systems annually, with a response deadline of July 26, 2026, delivered quarterly to the Seminole County Community Health Building. The Texas Health and Human Services Commission posted an RFI (HHS0017013) on April 3, 2026 to gather market intelligence on direct-to-manufacturer prescription programs, signaling early-stage state interest in restructuring pharmaceutical procurement models outside traditional pharmacy benefit manager and group purchasing organization channels.